Literature DB >> 15231874

Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.

Shereen Ezzat1, Lei Zheng, Sylvia L Asa.   

Abstract

We previously identified pituitary tumor-derived fibroblast growth factor receptor 4 (ptd-FGFR4), an alternatively transcribed N-terminally truncated cytoplasmic receptor isoform. Unlike wild-type FGFR4, ptd-FGFR4 facilitates cell transformation and results in pituitary tumor formation in transgenic mice. To investigate differences in the tumorigenic properties of FGFR4 and ptd-FGFR4, we examined their abilities to modulate cell adhesiveness. Introduction of ptd-FGFR4 into GH4 pituitary cells or NIH 3T3 fibroblasts resulted in significant reduction in cell adhesion to a collagen IV matrix compared with FGFR4- or empty vector-transfected cells. This adhesive difference was evident in the absence or presence of FGF stimulation. Furthermore, treatment with beta1-integrin neutralizing antibody markedly reduced adhesiveness in FGFR4-transfected cells but had little effect on the depressed adhesiveness of ptd-FGFR4-transfected cells. Unlike wild-type FGFR4, ptd-FGFR4 does not associate with neural cell-adhesion molecule (NCAM). Cells expressing FGFR4 demonstrate membranous N-cadherin with a noninvasive growth pattern identical to control GH4 cells when injected into immunodeficient mice. In contrast, ptd-FGFR4-expressing cells develop invasive tumors in vivo with marked loss of N-cadherin that localizes to the cytoplasm. Consistent with these changes, beta-catenin expression was diminished and its interaction with N-cadherin was disrupted in the presence of ptd-FGFR4, but both were intact in the presence of wild-type FGFR4. These data highlight the importance of membrane-anchored FGFR4 in assembling a multiprotein FGFR4 complex with NCAM and N-cadherin playing pivotal functions in maintaining normal cell adhesion. Disruption of distinct NCAM/N-cadherin proadhesive complexes by a tumor-derived FGFR4 isoform provides a novel mechanism beyond ligand independence that explains the pathobiology of proliferative and infiltrative but nonmetastatic neoplasms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231874     DOI: 10.1210/me.2004-0182

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  28 in total

1.  N-cadherin loss in POMC-expressing cells leads to pituitary disorganization.

Authors:  Ashley D Himes; Rachel M Fiddler; Lori T Raetzman
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.

Authors:  Xuegong Zhu; Lei Zheng; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.

Authors:  Boguslaw A Kwiatkowski; Irina Kirillova; Robert E Richard; David Israeli; Zipora Yablonka-Reuveni
Journal:  J Cell Physiol       Date:  2008-06       Impact factor: 6.384

Review 4.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 5.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

Review 6.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

7.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

8.  Premature differentiation and aberrant movement of pituitary cells lacking both Hes1 and Prop1.

Authors:  Ashley D Himes; Lori T Raetzman
Journal:  Dev Biol       Date:  2008-11-01       Impact factor: 3.582

Review 9.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

10.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.